Tag: subcutaneous immunoglobulin (scig) market trends

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The Subcutaneous Immunoglobulin (SCIG) Market Size Likely To Evolve From 2025 Through 2034?

The subcutaneous immunoglobulin (SCIG) market has seen swift expansion in recent years. It is anticipated to increase from $12.72 billion in 2024 to $14.39 billion in 2025, progressing at a compound annual growth rate (CAGR) of 13.1%. In prior periods, this growth was primarily driven by the rising occurrence of immunodeficiency disorders, a growing patient preference for home-based care options, enhanced treatment effectiveness, increased awareness and diagnosis rates, and the implementation of supportive reimbursement policies.

The market size for subcutaneous immunoglobulin (SCIG) is projected for significant expansion over the coming years. It is expected to reach $23.23 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 12.7%. This anticipated growth during the forecast period is primarily fueled by the increasing occurrence of neurological disorders and autoimmune diseases, coupled with heightened awareness and acceptance of immunoglobulin therapy. Furthermore, broadening applications in neurology and dermatology, along with the expansion of healthcare facilities, contribute to this trend. Key developments anticipated for the forecast period include advancements in drug delivery systems, a rising demand for home infusion therapies, breakthroughs in antibody therapy, novel approaches in formulations, and continued innovations in SCIG.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15935&type=smp

Which Industry Drivers Are Expected To Accelerate The Subcutaneous Immunoglobulin (SCIG) Market From 2025 To 2029?

The rising occurrence of secondary immunodeficiency conditions is anticipated to fuel the expansion of the subcutaneous immunoglobulin market in the future. These diseases involve an immune system that is diminished or impaired due to factors external to the immune system’s primary function. Several elements contribute to the commonness of secondary immunodeficiency diseases, including an aging populace, the application of immunosuppressive therapies, and exposure to environmental toxins. Subcutaneous immunoglobulin treatment delivers antibodies that fortify a compromised immune system, particularly in long-term illnesses like HIV or autoimmune conditions, effectively averting infections and bolstering immune functionality throughout therapy. As an illustration, the UK Health Security Agency, a UK-based government agency, stated in October 2023 that England saw 3,805 new HIV diagnoses in 2022, marking a 22% increase compared to the year before. Consequently, the growing incidence of secondary immunodeficiency diseases is acting as a catalyst for the growth of the subcutaneous immunoglobulin market.

What Are The Major Segments Identified In The Subcutaneous Immunoglobulin (SCIG) Market?

The subcutaneous immunoglobulin (scig) market covered in this report is segmented –

1) By Product Type: Immunoglobulin A (IgA), Immunoglobulin G (IgG), Immunoglobulin M (IgM)

2) By Application: Primary Immunodeficiency Disorders, Autoimmune Diseases, Neurological Disorders, Other Applications

3) By End-Use: Clinics, Hospitals, Homecare, Other End-Uses

Subsegments:

1) By Immunoglobulin A (IgA): IgA1, IgA2

2) By Immunoglobulin G (IgG): IgG1, IgG2, IgG3, IgG4

3) By Immunoglobulin M (IgM): Pentameric IgM, Hexameric IgM

Which Competitive Trends Are Defining The Subcutaneous Immunoglobulin (SCIG) Market Structure?

Key players in the subcutaneous immunoglobulin market are engaged in the development of subcutaneous human-klhw, an exclusive formulation featuring human immune globulins (Ig) aimed at strengthening the immune system. Subcutaneous human-klhw is intended for subcutaneous administration, designed to treat primary immunodeficiency diseases in the human body. For example, in March 2022, Grifols S.A., a pharmaceutical company based in Spain, launched XEMBIFY 20% subcutaneous immunoglobulin (SCIG). It is specifically formulated to address primary immunodeficiency, fulfilling a crucial medical demand for individuals with impaired immune systems. XEMBIFY is a pre-mixed formulation that simplifies the treatment procedure and enhances convenience for patients. It remains stable at room temperature for up to 24 months, eliminating the need for refrigeration during storage and transportation, which offers considerable advantages in various healthcare settings.

Which Major Industry Participants Are Leading The Subcutaneous Immunoglobulin (SCIG) Market Growth?

Major companies operating in the subcutaneous immunoglobulin (SCIG) market are Pfizer Inc., Johnson & Johnson, Prothena Corporation plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Behring, Lonza Group, Grifols S.A., Octapharma AG, Dr. Reddy’s Laboratories, Intas pharmaceutical Ltd., Emergent BioSolutions Inc., Kedrion Biopharma, LFB group, Biotest AG, Argenx SE, Bio Products Laboratory Ltd., ADMA Biologics Inc., Sino Biological Inc., Bharat Serums and Vaccines Limited (BSV), Kamada Pharmaceuticals, CinnaGen Co., Shire plc

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/subcutaneous-immunoglobulin-scig-global-market-report

How Do Regional Market Performances Compare Within The Subcutaneous Immunoglobulin (SCIG) Industry?

North America was the largest region in the subcutaneous immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the subcutaneous immunoglobulin (SCIG) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Subcutaneous Immunoglobulin (SCIG) Market Report:

https://www.thebusinessresearchcompany.com/customise?id=15935&type=smp

Browse Through More Reports Similar to the Global Subcutaneous Immunoglobulin (SCIG) Market 2025, By The Business Research Company

Immunoglobulins Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

Intravenous Immunoglobulin Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

Immunoglobulin E Ige Allergy Blood Tests Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/immunoglobulin-e-ige-allergy-blood-tests-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Much Will The Subcutaneous Immunoglobulin (SCIG) Market Be Worth By 2029?

The market for subcutaneous immunoglobulin (SCIG) has seen considerable growth in recent years, and its expansion will continue with the size increasing from $12.72 billion in 2024 to $14.39 billion in 2025. This represents a compound annual growth rate (CAGR) of 13.1%. Various factors have caused this historic growth, including a rise in cases of immunodeficiency disorders, a preference among patients for home-based care, improved therapeutic efficacy, increased awareness and diagnostic rates, and the growth of favorable reimbursement policies.

In the coming years, significant expansion is anticipated in the subcutaneous immunoglobulin (SCIG) market. It’s projected to swell to $23.23 billion by 2029, with a compound annual growth rate (CAGR) of 12.7%. The surge during the estimated period can be linked to the growing incidence of neurological disorders, heightened occurrence of autoimmune diseases, increased awareness and acceptance of immunoglobulin therapy, and extending applications in neurology and dermatology, along with broadened healthcare facilities. Key trends during this projected period include progress in drug delivery systems, an escalated demand for home infusion therapies, advancements in antibody therapy, novel developments in formulations, and innovative forays in SCIG.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15935&type=smp

Which Demand Drivers Are Strengthening The Subcutaneous Immunoglobulin (SCIG) Market?

The surge in secondary immunodeficiency diseases is predicted to fuel the expansion of the subcutaneous immunoglobulin market in the future. Such diseases result in a weakened or compromised immune system owing to factors apart from the immune system itself. These diseases’ prevalence is influenced by various elements such as an aging population, administering immunosuppressive treatments, and exposure to environmental toxins. Subcutaneous immunoglobulin therapy aids the impaired immune system by supplying antibodies, especially in chronic disorders like HIV or autoimmune diseases. It aids in preventing infections and ensuring immunological functionality during treatment. For instance, in October 2023, the UK Health Security Agency, a governmental organization based in the UK, reported 3,805 new HIV diagnoses in England in 2022, showing a 22% increase from the prior year. Consequently, the surge in secondary immunodeficiency diseases prevalence is spurring the expansion of the subcutaneous immunoglobulin market.

How Is The Global Subcutaneous Immunoglobulin (SCIG) Market Broken Down By Segment?

The subcutaneous immunoglobulin (scig) market covered in this report is segmented –

1) By Product Type: Immunoglobulin A (IgA), Immunoglobulin G (IgG), Immunoglobulin M (IgM)

2) By Application: Primary Immunodeficiency Disorders, Autoimmune Diseases, Neurological Disorders, Other Applications

3) By End-Use: Clinics, Hospitals, Homecare, Other End-Uses

Subsegments:

1) By Immunoglobulin A (IgA): IgA1, IgA2

2) By Immunoglobulin G (IgG): IgG1, IgG2, IgG3, IgG4

3) By Immunoglobulin M (IgM): Pentameric IgM, Hexameric IgM

Which Trends Are Likely To Redefine Growth Paths In The Subcutaneous Immunoglobulin (SCIG) Market?

Leading firms active in the subcutaneous immunoglobulin market are concentrating on the development of subcutaneous human-klhw. This unique blend contains human immune globulins (Ig) that boost the immune system. The use of subcutaneous human-klhw is primarily for subcutaneous application and has been designed to combat primary immunodeficiency diseases within the human body. For example, in March 2022, Grifols S.A., a pharmaceutical firm based in Spain, introduced XEMBIFY 20% subcutaneous immunoglobulin (SCIG), specially created to address primary immunodeficiency, catering to a substantial medical requirement for individuals with compromised immune systems. XEMBIFY, a ready-to-use formulation, has simplified the treatment procedure, thereby increasing patient ease. As it retains stability at room temperature for a duration of 24 months, there is no need for it to be refrigerated during storage and transit, making it particularly beneficial in numerous healthcare environments.

Who Are The Most Influential Companies In The Subcutaneous Immunoglobulin (SCIG) Market?

Major companies operating in the subcutaneous immunoglobulin (SCIG) market are Pfizer Inc., Johnson & Johnson, Prothena Corporation plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Behring, Lonza Group, Grifols S.A., Octapharma AG, Dr. Reddy’s Laboratories, Intas pharmaceutical Ltd., Emergent BioSolutions Inc., Kedrion Biopharma, LFB group, Biotest AG, Argenx SE, Bio Products Laboratory Ltd., ADMA Biologics Inc., Sino Biological Inc., Bharat Serums and Vaccines Limited (BSV), Kamada Pharmaceuticals, CinnaGen Co., Shire plc

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/subcutaneous-immunoglobulin-scig-global-market-report

Which Geographic Regions Are Creating Strong Demand In The Subcutaneous Immunoglobulin (SCIG) Market?

North America was the largest region in the subcutaneous immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the subcutaneous immunoglobulin (SCIG) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=15935&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Large Is the Cough And Cold Preparations Market Expected to Be in 2029?

The market for subcutaneous immunoglobulin (SCIG) has witnessed robust expansion in recent times. The market is forecasted to grow from $12.72 billion in 2024 to $14.39 billion in 2025, depicting a compound annual growth rate (CAGR) of 13.1%. Several factors contributing to the growth during the historic period include a higher occurrence of immunodeficiency disorders, a surge in patient preference for home-based treatments, improved therapeutic efficacy, an increase in awareness and diagnosis rates, as well as the development of favourable reimbursement policies.

In the forthcoming years, the subcutaneous immunoglobulin (SCIG) market is projected to experience significant expansion. It is forecasted to reach “$23.23 billion by 2029, growing at a compound annual growth rate (CAGR) of 12.7%. The anticipated growth during the projection period can be linked to the increasing incidence of neurological disorders, the surge in autoimmune diseases, growing consciousness and acceptance of immunoglobulin therapy, widening applications in neurological and dermatological fields, and the growth of healthcare facilities. Looking into the forecast period, key trends include the evolution in drug delivery systems, a growing demand for home infusion therapies, advancements in antibody therapy, innovations in medication formulations, and advancements in SCIG.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15935&type=smp

What Are The Contributors To Demand In The Cough And Cold Preparations Market?

The escalation in allergy occurrences is predicted to spur the expansion of the cough and cold preparations market during the projected period. Various respiratory allergies, including pollen, dust, mold, and pet allergies, are triggered by polluted indoor and outdoor air. Cough and cold remedies are commonly taken to tackle allergies that result in coughs and respiratory tract problems. For example, data from the European Academy of Allergy and Clinical Immunology – a non-profit entity for European clinicians, researchers, and healthcare professionals, suggests that by 2025, allergies will impact one in every three people in the European Union. Consequently, the rise in respiratory allergy cases will strengthen the need for cough and cold preparations, thereby influencing the market’s growth positively.

The subcutaneous immunoglobulin (scig) market covered in this report is segmented –

1) By Product Type: Immunoglobulin A (IgA), Immunoglobulin G (IgG), Immunoglobulin M (IgM)

2) By Application: Primary Immunodeficiency Disorders, Autoimmune Diseases, Neurological Disorders, Other Applications

3) By End-Use: Clinics, Hospitals, Homecare, Other End-Uses

Subsegments:

1) By Immunoglobulin A (IgA): IgA1, IgA2

2) By Immunoglobulin G (IgG): IgG1, IgG2, IgG3, IgG4

3) By Immunoglobulin M (IgM): Pentameric IgM, Hexameric IgM

What Notable Trends Are Shaping The Direction Of The Cough And Cold Preparations Market?

Prominent entities in the subcutaneous immunoglobulin market are working on the production of subcutaneous human-klhw, a distinct blend with human immune globulins (Ig) that boosts the body’s immunity. This formulation of subcutaneous human-klhw is designed for subcutaneous use and specifically focused on managing primary immunodeficiencies in human bodies. For example, in March 2022, Grifols S.A., a pharmaceutical firm based in Spain, introduced XEMBIFY 20% subcutaneous immunoglobulin (SCIG), exclusively engineered to address primary immunodeficiency, which caters to a significant healthcare requirement for individuals with compromised immune systems. XEMBIFY is a ready-to-use product that streamlines the treatment procedure and augments patient comfort. With a shelf-life of 24 months at ambient room temperature, this eliminates the requirement for refrigeration during storage and transport, making it very practical in various healthcare environments.

Who Are The Top-Ranked Companies In The Cough And Cold Preparations Market Today?

Major companies operating in the subcutaneous immunoglobulin (SCIG) market are Pfizer Inc., Johnson & Johnson, Prothena Corporation plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Behring, Lonza Group, Grifols S.A., Octapharma AG, Dr. Reddy’s Laboratories, Intas pharmaceutical Ltd., Emergent BioSolutions Inc., Kedrion Biopharma, LFB group, Biotest AG, Argenx SE, Bio Products Laboratory Ltd., ADMA Biologics Inc., Sino Biological Inc., Bharat Serums and Vaccines Limited (BSV), Kamada Pharmaceuticals, CinnaGen Co., Shire plc

https://www.thebusinessresearchcompany.com/report/subcutaneous-immunoglobulin-scig-global-market-report

How Is Cough And Cold Preparations Market Adoption Varying Across Different Regions And Sectors?

North America was the largest region in the subcutaneous immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the subcutaneous immunoglobulin (SCIG) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=15935&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Key Milestones in the Subcutaneous Immunoglobulin (SCIG) Market’s Growth Trajectory From 2025 To 2034?

The market for subcutaneous immunoglobulin (SCIG) has seen a swift expansion in the recent past. It is predicted to surge from $12.72 billion in 2024 to $14.39 billion in 2025, reflecting a compound annual growth rate (CAGR) of 13.1%. The notable growth in the past can be credited to factors like an upsurge in the occurrence of immunodeficiency disorders, an inclination towards home-based care among patients, improved therapeutic efficacy, an increase in recognition and diagnostic rates, as well as enhancement in favorable reimbursement policies.

Rapid expansion is foreseen for the subcutaneous immunoglobulin (SCIG) market in the approaching years, with predictions showing it swelling to $23.23 billion in 2029, showcasing a compound annual growth rate (CAGR) of 12.7%. This surge throughout the forecast period can be credited to the escalating occurrences of neurological disorders and autoimmune diseases, heightened awareness and acceptance of immunoglobulin therapy, expanded uses in neurology and dermatology, and the growth of healthcare facilities. The forecast period will also be marked by key tendencies including breakthroughs in drug delivery systems, an increased request for home infusion therapies, advancements in antibody therapy, formulation innovations, and fresh developments in SCIG.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15935&type=smp

Which Primay Drivers Are Accelerating Growth in the Subcutaneous Immunoglobulin (SCIG) Market?

The escalating incidence of secondary immunodeficiency diseases is predicted to fuel the expansion of the subcutaneous immunoglobulin market in the future. Secondary immunodeficiency diseases are disorders where the immune system is weakened or compromised due to factors other than the immune system itself. The increase in these diseases is influenced by various elements such as aging populations, immunosuppressive treatments, and environmental toxins. Subcutaneous immunoglobulin therapy provides antibodies which aid in enhancing the weakened immune system, particularly in chronic disorders like HIV or autoimmune diseases. This therapy helps prevent infections and maintains immunological function during treatment. For example, in October 2023, the UK Health Security Agency, a government agency based in the UK, reported an increase of 22% from the previous year, with 3,805 new HIV diagnoses in England in 2022. As such, the rising incidence of secondary immunodeficiency diseases is fueling the expansion of the subcutaneous immunoglobulin market.

Which Primary Segments of the Subcutaneous Immunoglobulin (SCIG) Market Are Driving Growth and Industry Transformations?

The subcutaneous immunoglobulin (scig) market covered in this report is segmented –

1) By Product Type: Immunoglobulin A (IgA), Immunoglobulin G (IgG), Immunoglobulin M (IgM)

2) By Application: Primary Immunodeficiency Disorders, Autoimmune Diseases, Neurological Disorders, Other Applications

3) By End-Use: Clinics, Hospitals, Homecare, Other End-Uses

Subsegments:

1) By Immunoglobulin A (IgA): IgA1, IgA2

2) By Immunoglobulin G (IgG): IgG1, IgG2, IgG3, IgG4

3) By Immunoglobulin M (IgM): Pentameric IgM, Hexameric IgM

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=15935&type=smp

Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Subcutaneous Immunoglobulin (SCIG) Market?# Market?

North America was the largest region in the subcutaneous immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the subcutaneous immunoglobulin (SCIG) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Which Technological Trends Are Reshaping the Subcutaneous Immunoglobulin (SCIG) Industry Dynamics?

In the subcutaneous immunoglobulin market, primary corporations are innovating with the creation of subcutaneous human-klhw, a unique blend that includes human immune globulins (Ig), enhancing the body’s immunity. This product, intended for subcutaneous use, is instrumental in treating primary immunodeficiency diseases. For example, Grifols S.A., a pharmaceutical corporation based in Spain, introduced XEMBIFY 20% subcutaneous immunoglobulin (SCIG) in March 2022. This innovation is designed specifically to address primary immunodeficiency and cater to individuals with compromised immune systems. XEMBIFY is a ready-made formula that simplifies treatment procedures and enhances patient comfort. Its stability at room temperature for up to two years eliminates the need for cool storage during transit, making it advantageous across various healthcare environments.

View the full report here:

https://www.thebusinessresearchcompany.com/report/subcutaneous-immunoglobulin-scig-global-market-report

What Parameters Are Used to Define the Subcutaneous Immunoglobulin (SCIG) Market?

Subcutaneous immunoglobulin (SCIG) refers to a method of administering immunoglobulin therapy in which the medication is delivered under the skin, rather than into a vein. This method allows for slower absorption of the medication, reducing the risk of side effects compared to intravenous administration. SCIG is used to treat various immune deficiencies, providing a convenient and effective way to boost the immune system.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15935

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has the Subcutaneous Immunoglobulin (SCIG) Market Growth Performance Trended Historically, And What Lies Ahead?_x000D_

In recent times, the subcutaneous immunoglobulin (SCIG) market has seen rapid expansion. The market size is projected to rise from $12.72 billion in 2024 to $14.52 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 14.1%. The expansion during the historical period has been driven by factors such as a heightened incidence of immunodeficiency ailments, an increase in patient inclination for home healthcare, improved therapeutic effectiveness, enhanced awareness and diagnosis rates, and progressive reimbursement policies._x000D_

_x000D_

#What Is the Forecast for the Subcutaneous Immunoglobulin (SCIG) Market Size Through 2029?#_x000D_

The market size for subcutaneous immunoglobulin (SCIG) is projected to experience considerable expansion in the coming years. It is forecasted to reach a worth of $24.29 billion in 2029, with a compound annual growth rate (CAGR) of 13.7%. This anticipated growth in the prediction period can be traced back to an increasing number of neurological disorders, a growing prevalence of autoimmune diseases, a surge in the acknowledgement and application of immunoglobulin therapy, as well as an expansion of its uses in neurology and dermatology, in addition to the growth of healthcare facilities. Significant trends for the forecast period encompass developments in drug delivery systems, a heightened demand for home-infused therapies, progress in antibody therapy, formulation advancements, and innovations specific to SCIG._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=15935&type=smp_x000D_

_x000D_

#What are the Key Market Players in Subcutaneous Immunoglobulin (SCIG) Market and How They’re Evolving?#_x000D_

Major companies operating in the subcutaneous immunoglobulin (SCIG) market are Pfizer Inc., Johnson & Johnson, Prothena Corporation plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Behring, Lonza Group, Grifols S.A., Octapharma AG, Dr. Reddy’s Laboratories, Intas pharmaceutical Ltd., Emergent BioSolutions Inc., Kedrion Biopharma, LFB group, Biotest AG, Argenx SE, Bio Products Laboratory Ltd., ADMA Biologics Inc., Sino Biological Inc., Bharat Serums and Vaccines Limited (BSV), Kamada Pharmaceuticals, CinnaGen Co., Shire plc_x000D_

_x000D_

#What Are the Primary Growth Drivers in the Subcutaneous Immunoglobulin (SCIG) Market?#_x000D_

There is an expected surge in the subcutaneous immunoglobulin market due to an increased occurrence of secondary immunodeficiency diseases. These ailments result from an impaired immune system that is affected by external factors, not the immune system itself. This prevalence is amplified by factors such as an aging demographic, exposure to environmental toxins, and immunosuppressive therapies. Subcutaneous immunoglobulin treatment supplies antibodies to bolster a weakened immune system, specifically in chronic diseases like HIV or autoimmune disorders, thereby preventing infections and contributing to immune function during treatment. For instance, the UK Health Security Agency noted a 22% increase in new HIV diagnoses in England in 2022 compared to the previous year with 3,805 cases in October 2023. Hence, a rise in secondary immunodeficiency diseases is contributing towards the growth of the subcutaneous immunoglobulin market. The growth trend in the subcutaneous immunoglobulin market is also expected to be driven by the rising incidence of neurological disorders. These disorders, impacting the nervous system, encompass anatomical, biochemical, or electrical abnormalities in the brain, spinal cord, or peripheral nerves such as acute spinal cord injury, Alzheimer’s dementia, ALS, ataxia, brain tumors, among others. The escalation of neurological disorders can stem from factors like an aging population, ecological toxins, genetic susceptibility, and changes in lifestyle. Subcutaneous immunoglobulin therapy offers potential benefits in treating neurological disorders by offering antibodies that modulate the immune response, lessen inflammation, and establish neuromuscular junction stability, possibly decelerating disease advancement and ameliorating symptoms. According to the Alzheimer’s Association, in March 2022, it was reported that 6.5 million Americans over the age of 65 are currently living with Alzheimer’s dementia, with an estimated rise to 13.8 million by 2060. Therefore, the mounting number of neurological disorders is augmenting growth in the subcutaneous immunoglobulin market._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=15935&type=smp_x000D_

_x000D_

#What Are the Leading Segments in the Global Subcutaneous Immunoglobulin (SCIG) Industry?#_x000D_

The subcutaneous immunoglobulin (SCIG) market covered in this report is segmented –_x000D_

_x000D_

1) By Product Type: Immunoglobulin A (IgA), Immunoglobulin G (IgG), Immunoglobulin M (IgM)_x000D_

2) By Application: Primary Immunodeficiency Disorders, Autoimmune Diseases, Neurological Disorders, Other Applications_x000D_

3) By End-Use: Clinics, Hospitals, Homecare, Other End-Uses_x000D_

_x000D_

Subsegments:_x000D_

1) By Immunoglobulin A (IgA): IgA1, IgA2_x000D_

2) By Immunoglobulin G (IgG): IgG1, IgG2, IgG3, IgG4_x000D_

3) By Immunoglobulin M (IgM): Pentameric IgM, Hexameric IgM_x000D_

_x000D_

#What Are the Key Market Trends in the Subcutaneous Immunoglobulin (SCIG) Industry?#_x000D_

Top-tier businesses in the subcutaneous immunoglobulin market are advancing their studies on subcutaneous human-klhw, a distinct preparation enriched with human immune globulins (Ig) designed to boost the immune system. The formulation is administered via the subcutaneous route, and is engineered to combat primary immunodeficiency diseases within humans. For instance, Grifols S.A., a pharmaceutical firm based in Spain, launched XEMBIFY 20% subcutaneous immunoglobulin (SCIG) in March 2022. This formulation is tailored specifically to manage primary immunodeficiency, responding to a key medical need of individuals with weak immune systems. The ready-to-use XEMBIFY simplifies treatment procedures and enhances patient compliance. Remarkably, it doesn’t require refrigeration as it can maintain stability at room temperature for up to 24 months. This characteristic can prove to be highly beneficial in diverse healthcare environments._x000D_

_x000D_

#Access The Full Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/subcutaneous-immunoglobulin-scig-global-market-report_x000D_

_x000D_

#What Is the Regional Outlook for the Subcutaneous Immunoglobulin (SCIG) Market?#_x000D_

North America was the largest region in the subcutaneous immunoglobulin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the subcutaneous immunoglobulin (SCIG) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa._x000D_

_x000D_

#Purchase The Full Report Today:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15935_x000D_

_x000D_

#This Report Delivers Insight On: #_x000D_

1. How big is the subcutaneous immunoglobulin (scig) market, and how is it changing globally?_x000D_

2. Who are the major companies in the subcutaneous immunoglobulin (scig) market, and how are they performing?_x000D_

3. What are the key opportunities and risks in the subcutaneous immunoglobulin (scig) market right now?_x000D_

4. Which products or customer segments are growing the most in the subcutaneous immunoglobulin (scig) market?_x000D_

5. What factors are helping or slowing down the growth of the subcutaneous immunoglobulin (scig) market?_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 2071930708_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the subcutaneous immunoglobulin (scig) industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Are the Projected Market Size and Growth Rates for the Subcutaneous Immunoglobulin (SCIG) Market From 2025 To 2029?

Recent years have seen a swift expansion in the subcutaneous immunoglobulin (SCIG) market size. The market, predicted to rise from $12.72 billion in 2024 to $14.52 billion in 2025, boasts a compound annual growth rate (CAGR) of 14.1%. The substantial growth during the historical period is a consequence of various factors including a surge in immunodeficiency disorders, an increase in patients opting for home-based care, improved therapeutic efficacy, greater awareness and diagnosis rates, and advantageous reimbursement policies.

In the forthcoming years, the market for subcutaneous immunoglobulin (SCIG) is poised for rapid expansion. The market is slated to reach $24.29 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 13.7%. Several factors will underpin this growth in the forecast period, such as expanding incidence of neurological disorders and autoimmune diseases, augmented awareness and acceptance of immunoglobulin treatment, broadening usage in the fields of neurology and dermatology, and enhanced healthcare infrastructure. Key trends during the forecast period will include progress in drug delivery systems, rising demand for therapies involving home infusion, advancements in antibody treatment, formulation innovations, and advances in SCIG.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15935&type=smp

What Are the Core Market Drivers Propelling Growth in the Subcutaneous Immunoglobulin (SCIG) Industry?

The surge in secondary immunodeficiency diseases is expected to stimulate the expansion of the subcutaneous immunoglobulin market in the future. These disorders, which stem from factors other than the immune system itself, weaken the immune system. Contributing factors to the prevalence of secondary immunodeficiency diseases include aging demographics, the use of immunosuppressive treatments, and environmental contaminants. Subcutaneous immunoglobulin therapy, which provides antibodies to bolster the compromised immune system, is particularly valuable in managing chronic disorders such as HIV and autoimmune diseases, as it prevents infections and aids in immunological function during treatment. For instance, the UK Health Security Agency, a UK government agency, reported a 22% increase in new HIV diagnoses in England in 2022, with a total of 3,805 cases noted in October 2023. As a result, the growing prevalence of secondary immunodeficiency diseases is spurring the growth of the subcutaneous immunoglobulin market. The surge in neurological disorders is another significant catalyst expected to fuel the expansion of the subcutaneous immunoglobulin market. Neurological disorders refer to any disorders related to the nervous system, including abnormalities in the brain, spinal cord, or peripheral nerves brought about by conditions like acute spinal cord injury, Alzheimer’s dementia, Amyotrophic Lateral Sclerosis (ALS), ataxia, brain tumors, and more. The rise in neurological disorders can be attributed to factors such as aging demographics, environmental pollutants, genetic factors, and lifestyle modifications. Subcutaneous immunoglobulin therapy comes in handy in managing neurological disorders as it provides antibodies that modulate the immune response, diminish inflammation, and stabilize neuromuscular junctions, potentially slowing disease progression and enhancing symptom management. For instance, the Alzheimer’s Association, a US-based nonprofit health organization, reported in March 2022 that there were 6.5 million Americans aged 65 and above living with Alzheimer’s dementia, a figure that is projected to hit 13.8 million by 2060. Therefore, the rise in neurological disorders is triggering the growth of the subcutaneous immunoglobulin market.

Which Key Market Segments Comprise the Subcutaneous Immunoglobulin (SCIG) Market and Drive Its Revenue Growth?

The subcutaneous immunoglobulin (SCIG) market covered in this report is segmented –

1) By Product Type: Immunoglobulin A (IgA), Immunoglobulin G (IgG), Immunoglobulin M (IgM)

2) By Application: Primary Immunodeficiency Disorders, Autoimmune Diseases, Neurological Disorders, Other Applications

3) By End-Use: Clinics, Hospitals, Homecare, Other End-Uses

Subsegments:

1) By Immunoglobulin A (IgA): IgA1, IgA2

2) By Immunoglobulin G (IgG): IgG1, IgG2, IgG3, IgG4

3) By Immunoglobulin M (IgM): Pentameric IgM, Hexameric IgM

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=15935&type=smp

Which Regions Are Driving the Next Phase of the Subcutaneous Immunoglobulin (SCIG) Market Growth?

North America was the largest region in the subcutaneous immunoglobulin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the subcutaneous immunoglobulin (SCIG) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Are the Strategic Trends Steering the Subcutaneous Immunoglobulin (SCIG) Market Direction?

Prominent players in the subcutaneous immunoglobulin market are involved in the creation of subcutaneous human-klhw, an exclusive blend composed of human immune globulins (Ig) designed to reinforce the immune system. This formulation is intended to be administered subcutaneously to treat primary immunodeficiency diseases in humans. An example of this is when Grifols S.A., a pharmaceutical company from Spain, unveiled XEMBIFY 20% subcutaneous immunoglobulin (SCIG) in March 2022. This solution has been made explicitly for treating primary immunodeficiency, thus fulfilling a considerable medical necessity for those with compromised immune systems. XEMBIFY offers a ready-made formulation that streamlines the treatment procedures, enhancing patient convenience. It can remain stable at room temperature up to 24 months, eliminating the requirement for refrigeration during its storage or transportation. This makes it highly convenient in various healthcare conditions.

View the full report here:

https://www.thebusinessresearchcompany.com/report/subcutaneous-immunoglobulin-scig-global-market-report

How Is the Subcutaneous Immunoglobulin (SCIG) Market Conceptually Defined?

Subcutaneous immunoglobulin (SCIG) refers to a method of administering immunoglobulin therapy in which the medication is delivered under the skin, rather than into a vein. This method allows for slower absorption of the medication, reducing the risk of side effects compared to intravenous administration. SCIG is used to treat various immune deficiencies, providing a convenient and effective way to boost the immune system.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15935

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What key factors are powering the surge in the subcutaneous immunoglobulin (scig) market right now?

There has been notable expansion in the size of the Subcutaneous Immunoglobulin (SCIG) market in the past few years. The market is projected to escalate from a valuation of $12.72 billion in 2024 to approximately $14.52 billion in 2025, representing a Compound Annual Growth Rate (CAGR) of 14.1%. Factors attributable to this historic growth include heightened incidence of immunodeficiency disorders, increased patient inclination towards home-based care, improved therapeutic efficacy, amplification in awareness and diagnostic rates, as well as the strengthening of beneficial reimbursement policies.

How fast Is the subcutaneous immunoglobulin (scig) market expected to grow, and what’s its future value?

The subcutaneous immunoglobulin (SCIG) market size is expected to see rapid growth in the next few years. It will grow to $24.29 billion in 2029 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to the growing prevalence of neurological disorders, increasing prevalence of autoimmune diseases, rising awareness and acceptance of immunoglobulin therapy, expanding applications in neurology and dermatology, expansion of healthcare facilities. Major trends in the forecast period include advancements in drug delivery systems, increasing demand for home infusion therapies, developments in antibody therapy, Innovations in formulations, and Innovations in SCIG.

Get your subcutaneous immunoglobulin (scig) market report here!

https://www.thebusinessresearchcompany.com/report/subcutaneous-immunoglobulin-scig-global-market-report

What are the leading drivers of growth in the subcutaneous immunoglobulin (scig) market?

The growth of the subcutaneous immunoglobulin market is anticipated to be driven by an increased prevalence of secondary immunodeficiency diseases. These diseases are characterized by a diminished or impaired immune system caused not by the immune system itself, but by external factors. This prevalence is fuelled by various factors including aging populations, immunosuppressive treatments, and environmental toxins. Subcutaneous immunoglobulin therapy helps bolster a compromised immune system, particularly in chronic conditions like HIV or autoimmune diseases, thereby preventing infections and bolstering immunological function during treatment. For instance, the UK Health Security Agency noted in October 2023, that there were 3,805 new HIV diagnoses in England in 2022, marking a 22% increase from the preceding year. Therefore, a rise in the prevalence of secondary immunodeficiency diseases is positively impacting the subcutaneous immunoglobulin market’s growth.

Subcutaneous Immunoglobulin (SCIG) Market Driver: Surge in Neurological Disorders Spurs Growth in the Subcutaneous Immunoglobulin Market

 

What are the key segments defining the subcutaneous immunoglobulin (scig) market?

The subcutaneous immunoglobulin (SCIG) market covered in this report is segmented –

1) By Product Type: Immunoglobulin A (IgA), Immunoglobulin G (IgG), Immunoglobulin M (IgM)

2) By Application: Primary Immunodeficiency Disorders, Autoimmune Diseases, Neurological Disorders, Other Applications

3) By End-Use: Clinics, Hospitals, Homecare, Other End-Uses

Subsegments:

1) By Immunoglobulin A (IgA): IgA1, IgA2

2) By Immunoglobulin G (IgG): IgG1, IgG2, IgG3, IgG4

3) By Immunoglobulin M (IgM): Pentameric IgM, Hexameric IgM

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15935&type=smp

Who are the key firms paving the way for growth in the subcutaneous immunoglobulin (scig) market?

Major companies operating in the subcutaneous immunoglobulin (SCIG) market are Pfizer Inc., Johnson & Johnson, Prothena Corporation plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Behring, Lonza Group, Grifols S.A., Octapharma AG, Dr. Reddy’s Laboratories, Intas pharmaceutical Ltd., Emergent BioSolutions Inc., Kedrion Biopharma, LFB group, Biotest AG, Argenx SE, Bio Products Laboratory Ltd., ADMA Biologics Inc., Sino Biological Inc., Bharat Serums and Vaccines Limited (BSV), Kamada Pharmaceuticals, CinnaGen Co., Shire plc

What emerging trends are influencing the growth of the subcutaneous immunoglobulin (scig) market?

Leading firms in the subcutaneous immunoglobulin market are creating subcutaneous human-klhw, a distinct compound comprising human immune globulins (Ig) that bolsters the immune defenses. This product, intended for subcutaneous application, is aimed at addressing primary immunodeficiency ailments in humans. For example, Grifols S.A., a pharmaceutical company based in Spain, unleashed XEMBIFY 20% subcutaneous immunoglobulin (SCIG) in March 2022. This product is solely designed for treating primary immunodeficiency, thus fulfilling a major medical requirement for individuals who have compromised immune systems. XEMBIFY is a readily available formulation making the treatment protocol simpler and enhancing patient comfort. It remains stable at room temperature for a period of up to 24 months thereby eliminating the requirement for refrigeration during storage and transit, proving exceedingly beneficial in numerous healthcare scenarios.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15935

Which geographic areas are influencing the growth of the subcutaneous immunoglobulin (scig) market?

North America was the largest region in the subcutaneous immunoglobulin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the subcutaneous immunoglobulin (SCIG) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Similar Reports By The Business Research Company:

Immunoglobulins Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/pd-1-and-pdl1-inhibitors-or-immune-checkpoint-inhibitors-global-market-report

Immune Health Supplements Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/immune-health-supplements-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Will the Subcutaneous Immunoglobulin (SCIG) Market’s Growth Rate Evolve Over the Forecast Period to 2034?

In recent times, there has been an impressive uptick in the market size of subcutaneous immunoglobulin (SCIG). This market is expected to expand from $12.72 billion in 2024 to $14.52 billion in 2025, reflecting a compound annual growth rate (CAGR) of 14.1%. The significant growth during the historical period is due to factors such as the rising incidence of immunodeficiency disorders, an increase in patient inclination towards home-based care, improved therapeutic effectiveness, and an increase in the rates of awareness and diagnosis. Additionally, favorable reimbursement policies have also contributed to this growth.

The market size for subcutaneous immunoglobulin (SCIG) is anticipated to experience swift expansion in the approaching years. The market is projected to escalate to $24.29 billion in 2029, with a compound annual growth rate (CAGR) of 13.7%. Factors contributing to this growth during the predicted period include the rising incidence of neurological conditions, the growing number of autoimmune diseases, increased awareness and acceptance of immunoglobulin treatment, broader usages in neurology and dermatology, and healthcare facilities expansion. Key trends expected during the projected period consist of improvements in drug delivery systems, heightened demand for home infusion therapies, advancements in antibody therapy, novel techniques in formulations, and innovative enhancements in SCIG.

What Strategic Factors Are Influencing the Accelerated Growth of the Subcutaneous Immunoglobulin (SCIG) Market?

The surge in secondary immunodeficiency diseases is anticipated to drive the expansion of the subcutaneous immunoglobulin market. These are conditions characterized by a diminished or compromised immune response due to causes other than the immune system itself. Factors like aging populations, the employment of immunosuppressive therapies, and environmental toxins contribute to the rise of these diseases. Subcutaneous immunoglobulin therapy is an effective method of boosting a weakened immune system, particularly in chronic conditions like HIV or autoimmune diseases, by delivering antibodies that prevent infections and assist with the maintenance of immunological functions during treatment. For instance, statistics from the UK Health Security Agency reported in October 2023 showed a 22% increase from the previous year with 3,805 new HIV diagnoses in England in 2022. Hence, the growth in the occurrence of secondary immunodeficiency diseases is fueling the subcutaneous immunoglobulin market. The subcutaneous immunoglobulin (SCIG) market is also seeing growth due to the rise in neurological disorders. These disorders of the nervous system, which include anatomical, biochemical, or electrical disruptions in the brain, spinal cord, or peripheral nerves, are on the rise due to factors like aging populations, environmental toxins, genetic factors, and lifestyle changes. Subcutaneous immunoglobulin therapy can be especially useful for these disorders as it provides antibodies that regulate the immune response, decrease inflammation, and secure neuromuscular junctions, potentially delaying the progression of the disease and alleviating symptoms. For instance, data from the Alzheimer’s Association in March 2022 disclosed that currently 6.5 million Americans over 65 are living with Alzheimer’s dementia, and projections suggest this figure could rise to 13.8 million by 2060. Therefore, the growth in neurological disorders is enhancing the expansion of the subcutaneous immunoglobulin market.

Explore Comprehensive Insights Into The Global Subcutaneous Immunoglobulin (SCIG) Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15935&type=smp

Who Are the Influential Players Reshaping the Subcutaneous Immunoglobulin (SCIG) Market Landscape?

Major companies operating in the subcutaneous immunoglobulin (SCIG) market are:

• Pfizer Inc.

• Johnson & Johnson

• Prothena Corporation plc

• GlaxoSmithKline plc

• Takeda Pharmaceutical Company Limited

What New and Evolving Trends Are Having a Lasting Impact on the Subcutaneous Immunoglobulin (SCIG) Market?

Leading corporations in the subcutaneous immunoglobulin market are developing a novel formulation called subcutaneous human-klhw, filled with human immune globulins (Ig) to enhance the body’s immune response. This formulation is designed for subcutaneous use, specifically to address primary immunodeficiency diseases. For example, the Spain-based pharmaceutical giant, Grifols S.A., rolled out XEMBIFY 20% subcutaneous immunoglobulin (SCIG) in March 2022, a product specifically tailored to treat primary immunodeficiency, and as such, responding to a critical healthcare need for individuals with compromised immune systems. XEMBIFY is a pre-packaged solution that simplifies the treatment routine and enhances patient convenience. With a shelf life of 24 months at room temperature, it eliminates the need for cold storage during transport and storage, and this feature makes it extremely versatile across different healthcare environments.

Secure Your Global Subcutaneous Immunoglobulin (SCIG) Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/subcutaneous-immunoglobulin-scig-global-market-report

Which Segments Play a Crucial Role in the Expansion of the Subcutaneous Immunoglobulin (SCIG) Market?

The subcutaneous immunoglobulin (SCIG) market covered in this report is segmented –

1) By Product Type: Immunoglobulin A (IgA), Immunoglobulin G (IgG), Immunoglobulin M (IgM)

2) By Application: Primary Immunodeficiency Disorders, Autoimmune Diseases, Neurological Disorders, Other Applications

3) By End-Use: Clinics, Hospitals, Homecare, Other End-Uses

Subsegments:

1) By Immunoglobulin A (IgA): IgA1, IgA2

2) By Immunoglobulin G (IgG): IgG1, IgG2, IgG3, IgG4

3) By Immunoglobulin M (IgM): Pentameric IgM, Hexameric IgM

Which Geographic Locations Are Critical to the Growth of the Subcutaneous Immunoglobulin (SCIG) Market?

North America was the largest region in the subcutaneous immunoglobulin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the subcutaneous immunoglobulin (SCIG) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

How Do Experts Define the Scope of the Subcutaneous Immunoglobulin (SCIG) Market?

Subcutaneous immunoglobulin (SCIG) refers to a method of administering immunoglobulin therapy in which the medication is delivered under the skin, rather than into a vein. This method allows for slower absorption of the medication, reducing the risk of side effects compared to intravenous administration. SCIG is used to treat various immune deficiencies, providing a convenient and effective way to boost the immune system.

Browse Through More Similar Reports By The Business Research Company:

Immunoglobulins Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/pd-1-and-pdl1-inhibitors-or-immune-checkpoint-inhibitors-global-market-report

Immune Health Supplements Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/immune-health-supplements-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: